NICE tells J&J … the price just ain’t right!

The National Institute for Health and Clinical Excellence (NICE) in the UK has issued draft guidance and a media release stating that it can not justify recommending the use of abiraterone acetate for the treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …